Combining therapies to improve treatment for non-Hodgkin lymphoma
Translation of a novel combination therapy approach for non-Hodgkin lymphoma
['FUNDING_U01'] · MAYO CLINIC ROCHESTER · NIH-11043487
This study is looking at a new treatment for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, to find out how to make current therapies work better, and it involves comparing cases in people and dogs to learn more about how to fight this cancer effectively.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11043487 on ClinicalTrials.gov |
What this research studies
This research investigates a new combination therapy for diffuse large B-cell lymphoma, the most common type of non-Hodgkin lymphoma, which often has limited treatment options. The study aims to understand why current immunotherapy approaches, like checkpoint inhibitors, are less effective for this type of cancer and to develop better therapeutic strategies. By comparing human and canine cases of lymphoma, researchers hope to gain insights into treatment responses and side effects in a setting that closely mimics human disease. The approach includes using an engineered oncolytic virus to enhance the immune response against the cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with diffuse large B-cell lymphoma, particularly those whose cancer has relapsed or is refractory to standard treatments.
Not a fit: Patients with other types of lymphoma or those who are not experiencing relapsed or refractory disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with non-Hodgkin lymphoma, improving their chances of recovery.
How similar studies have performed: Previous research has shown promise in using combination therapies and oncolytic viruses for cancer treatment, suggesting potential for success in this novel approach.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAIK, SHRUTHI — MAYO CLINIC ROCHESTER
- Study coordinator: NAIK, SHRUTHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers